Advertisement
Advertisement
PLX
Protalix BioTherapeutics, Inc. Common Stock
2.43
USDSponsored
-0.05
-2.02%
Aug 11, 15:59 UTC -4
Closed
After-Market
2.40
-0.04
-1.44%
PLX Earnings Reports
Positive Surprise Ratio
PLX beat 20 of 40 last estimates.
50%
Next Report
Tomorrow BMO
Date of Next Report
Aug 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$13.06M
/-$0.01
Implied change from Q1 26 (Revenue/ EPS)
-61.30%
/-104.55%
Implied change from Q2 25 (Revenue/ EPS)
-16.59%
/--
Protalix BioTherapeutics, Inc. Common Stock earnings per share and revenue
On May 13, 2026, PLX reported earnings of 0.22 USD per share (EPS) for Q1 26, beating the estimate of -0.01 USD, resulting in a 2278.22% surprise. Revenue reached 33.75 million, compared to an expected 11.58 million, with a 191.38% difference. The market reacted with a +1.05% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 2 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 13.06 million USD, implying an decrease of -104.55% EPS, and decrease of -61.30% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
LENZ Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.02
Surprise
+6.95%
Codexis, Inc.
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+7.67%
Seer, Inc. Class A Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.31
Surprise
-12.56%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Mineralys Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.54
Actual
-$2.85
Surprise
-422.26%
Imunon, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.94
Actual
-$0.54
Surprise
+42.83%
FAQ
What were Protalix BioTherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Protalix BioTherapeutics, Inc. Common Stock reported EPS of $0.22, beating estimates by 2278.22%, and revenue of $33.75M, 191.38% above expectations.
How did the market react to Protalix BioTherapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 1.05%, changed from $1.91 before the earnings release to $1.93 the day after.
When is Protalix BioTherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 12, 2026.
What are the forecasts for Protalix BioTherapeutics, Inc. Common Stock's next earnings report?
Based on 2
analysts, Protalix BioTherapeutics, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $13.06M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement